By use of monoclonal antibodies cross-reactive with Marek's disease virus and herpesvirus of turkeys, three glycoproteins (for Marek's disease virus, gpllS/110, gp63, and gp5O; for herpesvirus of turkeys, gpllS, gp62 and gp52) related to virus neutralization were identified. Immunization of chickens or rabbits with these glycoproteins purified by affinity chromatography resulted in production of neutralizing antibodies.
Marek's disease virus (MDV) is the etiological agent of Marek's disease (MD), a highly contagious malignant lymphoma of chickens. Herpesvirus of turkeys (HVT) has been successfully used as an MD vaccine. All strains of MDV and HVT are closely related antigenically (1, 13, 16) . Three main antigens, "A," "B," and "C," are detected by immunodiffusion analysis of both cell extracts and culture fluids of MDV-infected cells (2) . The A antigen common to MDV and HVT has been studied mainly and has been characterized as a glycoprotein (14) . Recently, we found by sodium dodecyl sulfate-polyacrylamide gel electrophoresis that most of the virus-specific polypeptides in cells productively infected with MDV and HVT possess cross-reactive antigenic determinants (7) . In spite of these antigenic similarities, the two viruses probably have <5% DNA homology (4, 8, 10) . Therefore, further studies on the modes of the immune responses to these viral polypeptides are required for a clear understanding of the vaccinal immunity of HVT against MD.
Since the principal target antigens involved in virus neutralization are virus-specific glycoproteins, analysis of glycoproteins cross-reactive between MDV and HVT is a prerequisite for studies on immunity to MD induced by HVT. Hyperimmune antisera against the antigens common to MDV and HVT were shown to neutralize the infectivity of both viruses (12) . The common antigens include glycoproteins with molecular weights (MW) of 33,000 to 46,000 (11) . Moreover, immunization of chickens with HVT-infected, cell membrane-associated glycoproteins with MWs of 100,000 to 120,000 resulted in production of neutralizing antibody and partial protection against MD (17) . One mouse hybridoma obtained from an HVT-immunized mouse has been reported to produce monoclonal antibody reactive with homologous HVT, but not with MDV, in the serum neutralization test, but the antigenic component recognized by the monoclonal antibody has not been identified yet (9) . The cross-reactive antigens of MDV and HVT involved in virus neutralization have not been identified with monoclonal antibodies. The purpose of the present study was to identify the polypeptides responsible for neutralization of HVT and MDV, using monoclonal antibodies cross-reacting with these viruses.
MDV strain BC-1 and HVT strain 01 were propagated in specific-pathogen-free chicken embryo fibroblasts (CEF) as * Corresponding author. described previously (6) . For radiolabeling of cells, mockinfected and infected cells were labeled with 100 ,uCi of L-[35S]methionine (1,250 Ci/mmol) or 100 ,uCi of D-[6-3H]glucosamine hydrochloride (30.3 Ci/mmol) per ml from 24 to 48 h postinfection as described previously (7) . The methods used for production and culture of hybridomas and screening procedures for MDV-or HVT-specific antibodies were described in detail elsewhere (5) . The antigens for immunization were purified from extracts of MDV-or HVT-infected CEF by affinity chromatography on cyanogen bromideactivated Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden) coupled with chicken anti-MDV or anti-HVT serum immunoglobulin G (IgG), respectively, as described previously (5) . The virus-specific antibodies were detected by the indirect immunofluorescence (IF) test, using infected CEF fixed with cold acetone as described previously (5). Clones producing virus-specific antibodies were injected intraperitoneally into BALB/c mice, and the resulting ascites fluids were harvested and clarified. For preparation of hyperimmune sera against the antigens recognized by monoclonal antibodies, the antigens were purified on cyanogen bromide-activated Sepharose 4B coupled with the immunoglobulin fraction from ascites fluid containing monoclonal antibody, as described previously (5) . Rabbits or specificpathogen-free chickens were immunized by intramuscular injection of purified antigens mixed with Freund complete adjuvant and then 4 weeks later with the same antigens without adjuvant. The techniques used for immunoprecipitation of virus-specific antigens from cell lysates or culture media with antibodies and for sodium dodecyl sulfatepolyacrylamide gel electrophoresis were as described previously (6) . The subclasses of monoclonal antibodies were determined by immunodiffusion with a cell lysate and classspecific immunoglobulin antisera (Nordic Immunological Laboratories, Tilburg, The Netherlands) as described by Volk et al. (15) . Tissue culture fluids of hybridoma cells and hyperimmune sera were tested for neutralization of cell-free HVT and MDV as described by Lee et al. (9) .
We prepared a series of monoclonal antibodies against specific and cross-reactive polypeptides of HVT and MDV (5) . Of these antibodies, two groups of monoclonal antibodies reacted with virus-specific glycoproteins. One Virol., in press) ( Fig. 1E ). These glycoproteins, corresponding to the A antigen of MDV and HVT (1, 2), were tentatively named gA of HVT and MDV. The other group included 14 monoclonal antibodies reacting with the glycoproteins that differed from gA as described below (Fig. 1) . These glycoproteins were tentatively named gB. The properties of ascites fluid containing the monoclonal antibodies reacting with gB are shown in Table 1 . Most ascites fluids showed high titers against both MDV-and HVT-infected cells, but not against uninfected cells. It was found by membrane IF that these monoclonal antibodies reacted with the cell surface of unfixed infected CEF, although the intensity of their reaction was weaker than that of gA. Two ascites fluids containing H3 and H14 antibodies reacted only with HVT-infected cells, not with MDV-infected cells. Since the monoclonal antibodies against HVT-and MDV-gA did not neutralize cell-free HVT (data not shown), monoclonal antibodies against HVT-and MDV-gB were tested for neutralizing activity (Table 1) . Of these, M51 and H35 antibodies, cross-reactive with HVT and MDV, neutralized >50% of the infectivity of HVT. However, these same antibodies reduced MDV plaques at rates of 41 and 38%, respectively. This incomplete neutralization could be due to the large amount of gB antigen present in the cell-free virus preparation which may interfere with the neutralization. Because of the highly cell-associated nature of MDV, a large amount of MDV-infected CEF was required to prepare sufficient cell-free infectious virus. Monoclonal antibodies reactive with gB belong to several subclasses of immunoglobulin ( Table 1 ). The predominant isotype of immunoglobulin was IgGl, which reacts weakly with Staphylococcus aureus protein A (3). Therefore, the antigen-antibody complexes were mixed with rabbit antimouse IgG for immunoprecipitation, using these antibodies, and then collected with S. aureus protein A as described previously (Ikuta et al., in press).
Immunoprecipitation experiments with monoclonal antibodies reactive with gB were made on HVT-and MDVinfected cells labeled with [35S]methionine or [3H]glycosamine from 24 to 48 h postinfection (Fig. 1) . Examples of the immunoprecipitates of cell lysates with H16 (Fig. 1A) , H14 (Fig. 1B) , and M51 (Fig. 1C) antibodies are shown. H14 antibody was specific to HVT, and the other two antibodies, H16 and M51, which were obtained from mice immunized with HVT and MDV antigens, respectively, were crossreactive with MDV and HVT by the IF test (Table 1) . Three HVT-specific polypeptides with MWs of 115,000, 62,000, and 52,000 were precipitated with all of the monoclonal antibodies shown in Table 1 , indicating that these polypeptides share common antigenic determinants. However, when the cell lysates of MDV-infected cells were examined for immunoprecipitation (Fig. 1A to C) , it was found that MDVspecific polypeptides were very slightly precipitated with either H16 or M51 antibody, although these antibodies were strongly reactive with both HVT-and MDV-infected cells in the IF test (Table 1 Figure 1D shows that these three HVT-specific polypeptides were labeled with [3H]glucosamine, indicating that they are glycoproteins. They were tentatively named gpll5, gp62, and gp52 of HVT-gB. By labeling with [3H]glucosamine, at least three glycoproteins, gpllS/110, gp63, and gp5O, were identified as MDV-gB with M51 antibody (Fig. 1D) , although their glycoprotein bands were weaker than those of HVT-gB. Of the three glycoprotein bands of HVT-gB or MDV-gB, the bands of HVT-gp62 and MDV-gp63 were most strongly labeled with [3H]gluqosamine. Since the bands of the polypeptides (indicated by arrows in Fig. 1) were also detected in immunoprecipitates of mock-infected cells or medium, they seem to be nonspecific polypeptides.
When infected culture medium labeled with [35S]methionine (Fig. 1C) or [3H]glucosamine (data not shown) was immunoprecipitated with M51 antibody, no MDV-or HVTgB was detectable. MDV-and HVT-gA in the MW ranges of 54,000 to 70,000 and 50,000 to 64,000, respectively, were immunoprecipitated with M34 antibody cross-reactive with MDV-and HVT-gA from the infected culture media (Fig.  1E) . These results indicate that MDV-and HVT-gB differ from MDV-and HVT-gA.
By the IF test, H3 or H14 antibody was found to be specific to HVT, whereas the other antibodies were crossreactive with MDV and HVT (Table 1 ). In addition, the infectivity of HVT was neutralized with M51 or H35 antibody, but not with M8 or M67 (Table 1) . However, all of these monoclonal antibodies reacted with three polypeptides of HVT-gB (Fig. 1A to C) . These results suggest that at least three types of antigenic determinants are located on all three polypeptides. The first one is an HVT-specific determinant reactive with H3 or H14 antibody. The second one is a crossreactive determinant, not related to virus neutralization, which is reactive with M8 or M67 antibody. The third is a cross-reactive determinant, related to virus neutralization, which is reactive with M51 or H35 antibody. MDV-gB appears to contain at least two antigenic determinants. Both are cross-reative with HVT. One neutralized HVT and MDV and the other did not.
Since the weaker immunoprecipitation of MDV-specific polypeptides with monoclonal antibodies could be due to a weak reaction between these antigens and antibodies, hyperimmune antisera against gB of MDV and HVT were prepared from rabbits or chickens immunized with HVT-and MDV-gB and were purified from HVT-and MDV-infected cell lysates by affinity chromatography coupled with M51 monoclonal antibody. The antisera obtained were repeatedly absorbed with uninfected CEF fixed with 0.5% glutaraldehyde. The IF titers of these antisera are listed in Table 2 gave essentially similar patterns (data not shown). Rabbit or chicken antiserum against HVT-gB and rabbit antiserum against MDV-gB neutralized both HVT and MDV (Table 2) . These results suggest that HVT-and MDV-gB are the primary components responsible for generating neutralizing antibody in vivo. However, less neutralizing antibody was detected in a chicken immunized with MDV-gB, possibly due to the low antibody response in the chicken (Table 2) .
It is interesting that the monoclonal antibodies used here immunoprecipitated at least three glycoproteins (HVTgpllS, -gp62, and -gp52; MDV-gpllS/110, -gp63, and -gpSO). Recent studies in our laboratories indicated that HVT-gpll5 and MDV-gpllS/110 are the precursors of HVT-and MDVgB, respectively, and are processed to HVT-gp62 and -gp52 and MDV-gp63 and gpSO, respectively, at least in part by sialylation. In addition to these glycoproteins, [3H]glucosamine-labeled bands below MDV-gpSO and HVT-gp52 (indicated by arrowheads in Fig. 1D and G) appeared to be virus specific. However, the corresponding discrete bands were not identified in the immunoprecipitates labeled with [35S]methionine. The significance of these bands for the processing steps of gB is under investigation.
Wyn-Jones and Kaaden (17) isolated glycoproteins from membrane fractions of HVT-infected cells. They found that glycoproteins in the MW range of 110,000 to 120,000 induced neutralizing antibodies in rabbits and chickens. At present, it is not known whether the glycoproteins that they isolated are identical to HVT-gB in this study. Further studies are in progress on the structural similarities of HVT-and MDV-gB and on whether immunization with purified HVT-gB will protect chickens from MD.
